Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.

        Print
| Source: Pain Therapeutics, Inc.

AUSTIN, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that yesterday it received correspondence from Pfizer, Inc. (NYSE:PFE).

This correspondence is available at: http://investor.paintrials.com/sec.cfm.

The company furnished the correspondence with the Securities and Exchange Commission pursuant to the submission of a Current Report on Form 8-K.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit www.paintrials.com.

For More Information Contact:

Peter S. Roddy
Vice President and Chief Financial Officer
Pain Therapeutics, Inc.

(512) 501-2450